AtriCure Inc. (NASDAQ:ATRC) saw some unusual options trading activity on Wednesday. Investors acquired 2,751 call options on the stock. This represents an increase of 1,056% compared to the typical volume of 238 call options.
NASDAQ:ATRC opened at $30.81 on Thursday. AtriCure has a 12 month low of $14.88 and a 12 month high of $36.49. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.62 and a quick ratio of 1.96. The firm has a market cap of $1.16 billion, a PE ratio of -37.12 and a beta of 0.22.
AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, November 1st. The medical device company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02). AtriCure had a negative return on equity of 16.92% and a negative net margin of 10.41%. The company had revenue of $49.90 million for the quarter, compared to analyst estimates of $49.90 million. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. The company’s quarterly revenue was up 18.2% on a year-over-year basis. On average, equities analysts predict that AtriCure will post -0.9 EPS for the current year.
Several large investors have recently bought and sold shares of ATRC. Federated Investors Inc. PA acquired a new stake in shares of AtriCure during the third quarter worth $34,000. Ibex Investors LLC acquired a new stake in shares of AtriCure during the third quarter worth $204,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of AtriCure during the third quarter worth $210,000. BlueMountain Capital Management LLC lifted its stake in shares of AtriCure by 121.8% during the second quarter. BlueMountain Capital Management LLC now owns 14,904 shares of the medical device company’s stock worth $403,000 after buying an additional 8,184 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in shares of AtriCure during the third quarter worth $521,000. Institutional investors and hedge funds own 81.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2019/01/17/atricure-sees-unusually-large-options-volume-atrc.html.
AtriCure Company Profile
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Further Reading: What is net income?
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.